Hypoxia in plaque macrophages: a new danger signal for interleukin-1β activation?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Role of glycolysis in diabetic atherosclerosis.World journal of diabetes · 2023
   Review
2. Inflammasomes: a preclinical assessment of targeting in atherosclerosis.Expert opinion on therapeutic targets · 2020
   Review
3. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.Molecular cancer · 2019
   Article
4. Regulation of macrophage immunometabolism in atherosclerosis.Nature immunology · 2018
   Review
5. Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis.Current pharmaceutical design · 2017
   Review
6. Potential contributions of intimal and plaque hypoxia to atherosclerosis.Current atherosclerosis reports · 2015
   Review

Corrections and comments

• Comment on
  Moderate hypoxia potentiates interleukin-1β production in activated human macrophages.2014

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as